However, in two large pan-cancer retrospective studies, which enrolled 451 and 375 SETD2-mutated tumors, respectively, SETD2 loss of function correlated with a higher tumor mutation burden and a better response to ICI immunotherapy [60,61]. Here, SETD2 is linked to cancer.